NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

CompletedN/A

Sponsor: AstraZeneca

Conditions: Carcinoma, Small Cell

Countries: Japan

To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

-Patients with extensive stage small cell lung cancer who are receiving the product in combination with platinum agent and etoposide.

Exclusion Criteria:

-Patients who have no treatment history with the product (i.e.,durvalumab)

Locations (18)

Chiba, Japan
Fukuoka, Japan
Gunma, Japan
Hokkaido, Japan
Hyōgo, Japan
Kanagawa, Japan
Miyagi, Japan
Nagano, Japan
Nagasaki, Japan
Nara, Japan
Numakunai, Japan
Okayama, Japan
Osaka, Japan
Saitama, Japan
Shizuoka, Japan
Tokyo, Japan
Tottori, Japan
Wakayama, Japan